Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Annexa

Bristol-Myers Squibb (BMS) building

BMS creates US academic tie-up to foster biopharma research

Partnership with investment firm could also boost its pipeline

- PMLiVE

Boehringer/Lilly’s Jardiance approved in US

But the FDA wants four post-marketing studies of the SGLT-2 diabetes drug

Boehringer continues award-winning ChatAFib tweet chat

Its next social media discussion follows the programme's Communiqué win

Boehringer Ingelheim headquarters

Boehringer submits COPD combo in EU

Combines Spiriva and Striverdi

- PMLiVE

ADA: Lilly/Boehringer insulin glargine matches Lantus

Biosimilar demonstrates equal efficacy to Sanofi’s big-selling diabetes treatment

- PMLiVE

Boehringer launches ASCO blog to talk about lung cancer

Not Just One Disease set to cover a range of topics, including the patient journey

Bristol-Myers Squibb (BMS) building

BMS files fixed-dose HIV combination in US

Combines Reyataz with Gilead Sciences' cobicistat

Bristol-Myers Squibb (BMS) building

BMS strikes $350m deal to boost its immuno-oncology pipeline

Will collaborate with US biotech Five Prime Therapeutics

Bristol-Myers Squibb (BMS) building

BMS’ novel HIV drug clears phase II trial

Entry inhibitor BMS-660368 moves closer to first-in-class approval

- PMLiVE

Lilly/Boehringer’s empagliflozin faces US approval delay

FDA cites manufacturing issues with the new diabetes drug

Bristol-Myers Squibb (BMS) building

BMS’ oral hepatitis C regimen gets breakthrough status

Combines daclatasvir and asunepravir

Twitter praises Boehringer’s use of its platform

Corporate case study highlights pharma company's use of tweet chats

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links